Tech

How Digital Payments Can Disrupt The Cannabis Industry

The cannabis industry is booming. Sales for state-legal cannabis businesses are projected to reach close to $30 billion by 2025. Yet most of these businesses are still reliant on cash to run their business. And that can cause a lot of trouble.

But digital payments — and FinTech companies like AeroPay — have the opportunity to disrupt this long underserved industry. Here’s how:

More states allowing telehealth consults for cannabis authorization

Until recently, the term “telehealth” was known in the medical community, but not the cannabis community.

Since the COVID-19 outbreak sent the country into lockdown, medical marijuana users in many states can now check in with a health care provider by video for authorization, rather than an in-person meeting.

According to MPP.org, 31 states currently allow telemedicine for cannabis patients – 11 of which have temporarily altered their laws as a result of the current coronavirus pandemic.

In Cannabis Industry, Profitability and Data Security Go Hand-in-Hand

The issues surrounding legalized cannabis and data security create a multi-front battle that can be incredibly challenging from a legal and technological perspective.

No longer operating in the margins, the highly profitable, and highly regulated, legalized cannabis industry has ably, as well as nimbly, pushed its sales through to mainstream business. Total legal sales of cannabis in the U.S.

How marijuana laws complicate scientists' search for crucial answers about cannabis, hemp

In the humid rooms of industrial-sized greenhouses on the outskirts of Geneva live hundreds of hemp plants of more than 60 varieties, a large part of Cornell University’s hemp breeding and genetics program.

At Surge Laboratory, a short walk from the greenhouses, doctoral student Jacob Toth preps several test tubes for analysis. Their orange-hued broth contains genes responsible for making cannabinoids, the 100-plus chemicals found in the cannabis plant.

Cannabis research stalled by federal inaction

US scientists face numerous barriers to studying health effects of cannabis

Researchers in the US who want to investigate the medical benefits and risks of cannabis are frustrated. They would like to evaluate the wide array of cannabis products sold in states where cannabis is legal, but federal law prohibits them from doing so because cannabis is still illegal at the federal level.

Post-Pandemic Cannabis: Are Amazon, Uber, And Other Mainstream Delivery Services, The Future?

There are hints that cannabis delivery using mainstream widespread delivery services could happen someday in the same way that alcohol is delivered.

It’s hard to say where we are in the COVID-19 pandemic right now, as infections and deaths continue to rise. But there have been movements in the cannabis industry that are changing the way the industry operates amid the pandemic that may stay post-pandemic.

Drug Trial Planned for Synthetic Cannabinoid COVID-19 Treatment

FSD Pharma has received FDA permission to design and submit an application for a new trial using a synthetic cannabinoid-based drug in the treatment of COVID-19.

Philadelphia, Pennsylvania-based cannabis company FSD Pharma has been granted permission by the Food and Drug Administration to submit an Investigational New Drug Application for a clinical trial using a synthetic cannabinoid drug called ultramicronized palmitoylethanolamide (micro PEA) to treat COVID-19.